Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1819
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Rochester, MN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Rochester, MN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 493–504 of 1,819 matching trials with a site at Mayo Clinic, Rochester, MN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

NCT07161037
Site status not listed — check the official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
26
States / cities
Alabaster, Alabama • Birmingham, Alabama • Los Angeles, California + 21 more
Recruiting Phase 1Phase 2 Interventional

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

NCT06525636
Status at this site: Not yet recruiting
Conditions
X-linked Hypophosphatemia
Interventions
KK8123
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
Conditions
Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
Interventions
VDyne Transcatheter Tricuspid Valve Replacement System
Device
Lead sponsor
VDyne, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Detriot, Michigan • Minneapolis, Minnesota + 7 more
Conditions
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions
Inobrodib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • San Francisco, California • Jacksonville, Florida + 18 more
Conditions
Metabolic Acidosis
Interventions
Sodium bicarbonate, Tris-hydroxymethyl Aminomethane
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting Phase 1Phase 2 Interventional

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639
Status at this site: Recruiting
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions
TRX319, Bendamustine
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more
Conditions
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions
VV169
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting No phase listed Observational

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

NCT06271291
Status at this site: Recruiting
Conditions
Pancreatic Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 8 more
Active, not recruiting Phase 1 Interventional

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

NCT06005740
Site status not listed — check the official record
Conditions
Advanced Solid Tumor, Hepatocellular Carcinoma
Interventions
TORL-4-500
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 5 more
Recruiting Not applicable Interventional

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

NCT04592445
Status at this site: Recruiting
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF
Interventions
Greater Splanchnic Nerve Ablation, Sham Control
Device
Lead sponsor
Axon Therapies, Inc.
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 17 more
Conditions
Long QT Syndrome (LQTS) 2
Interventions
baseline lead-in, THRV-1268
Other · Drug
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more
Recruiting No phase listed Observational

Continuous Monitoring of Microvascular Anastomoses: An Observational Trial

NCT07823283
Status at this site: Recruiting
Conditions
Head and Neck Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.